Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: AlienTech who wrote (7970)	5/9/1998 6:06:00 PM
From: EyeDrMike	Read Replies (3) \| Respond to of 23519

i meant to comment on a post recently, i think it was Frosty's, and forgot. The topic of "cures" from ED treatment came up. In essence, some who try ED treatments such as MUSE and Viagra will be "cured", the reasoning being its psychological ED, the meds do nothing a placebo wouldn't do, and they no longer need the "cure" If you read the bottom part of this Astra release, you'll see its already been reported as happening. The Astra press release on its launching of the MUSE product: Marketletter Marketletter Publications Ltd. (UK)) Information Access Company. Monday, February 23, 1998 UK Launch Of Astra's MUSE Subscription: 449 British Pound Sterling per year as of 1/97. Published weekly. Contact Marketletter (Publications) Ltd., 54/55 Wilton Rd., London SW1V 1DE, UK. Astra Pharmaceuticals has launched its transurethral product for the treatment of male erectile dysfunction of primarily organic etiology, MUSE (alprostadil), a synthetic form of the vasodilator prostaglandin E1, in the UK. It was launched in its first market, the USA, in January last year. A Phase III clinical trial of MUSE, which is licensed from VIVUS Pharmaceuticals, demonstrated that it was effective in 65.9% of patients in the clinic, while 64.9% of men in the home treatment phase achieved intercourse at least once versus 18.6% of placebo receivers. The recommended starting dose of MUSE is 250mcg, which must be titrated under medical supervision until the correct dose is found, following which the patient can use the product at home. Only two doses are recommended in every 24-hour period. The cost to the National Health Service for a pack of six MUSE will be L54.84 ($89.37; 125mcg), L59.70 (250mcg and 500mcg) and L61.08 (1,000mcg). It was noted at an Astra press meeting that there needs to be a shift towards the general practitioner treating patients with erectile dysfunction. However, John Pryor, a consultant and urologist, pointed out that the cost of MUSE "is probably an issue," despite the fact that the treatment has a significant effect on quality of life and that in practice patients are quite reasonable with their demand for the product. He also noted that approximately 7% of men regain spontaneous erection following treatment. Astra is also the license holder for the rest of Europe, Australia, New Zealand and South America.